Stay updated on Fazirsiran Safety & Efficacy Clinical Trial

Sign up to get notified when there's something new on the Fazirsiran Safety & Efficacy Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Fazirsiran Safety & Efficacy Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:18:19.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the number of participants enrolled in the study evaluating the safety, efficacy, and tolerability of Fazirsiran Injection for individuals with alpha-1 antitrypsin deficiency (AATD). This change may reflect an adjustment in the total enrollment count for the clinical trial.
    Difference
    0.1%
    Check dated 2024-06-06T14:31:43.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying the need for a diagnosis of AATD and liver biopsy results, among other health and consent requirements. Previously, no information was provided for collaborators and investigators.
    Difference
    17%
    Check dated 2024-05-22T21:13:37.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:47:40.000Z thumbnail image

Stay in the know with updates to Fazirsiran Safety & Efficacy Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Fazirsiran Safety & Efficacy Clinical Trial page.